CN110105429A - Glu-Leu-Phe-Tyr-Val五肽,其合成,活性和应用 - Google Patents
Glu-Leu-Phe-Tyr-Val五肽,其合成,活性和应用 Download PDFInfo
- Publication number
- CN110105429A CN110105429A CN201910381694.0A CN201910381694A CN110105429A CN 110105429 A CN110105429 A CN 110105429A CN 201910381694 A CN201910381694 A CN 201910381694A CN 110105429 A CN110105429 A CN 110105429A
- Authority
- CN
- China
- Prior art keywords
- leu
- val
- tyr
- phe
- glu
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000000694 effects Effects 0.000 title abstract description 13
- 230000015572 biosynthetic process Effects 0.000 title description 2
- 238000003786 synthesis reaction Methods 0.000 title description 2
- 208000007536 Thrombosis Diseases 0.000 claims abstract description 21
- 238000002360 preparation method Methods 0.000 claims abstract description 4
- 239000002260 anti-inflammatory agent Substances 0.000 claims abstract description 3
- 239000002246 antineoplastic agent Substances 0.000 claims abstract description 3
- 229940041181 antineoplastic drug Drugs 0.000 claims abstract description 3
- 239000003527 fibrinolytic agent Substances 0.000 claims abstract description 3
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims description 13
- 238000006555 catalytic reaction Methods 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 9
- MVEAAGBEUOMFRX-UHFFFAOYSA-N ethyl acetate;hydrochloride Chemical compound Cl.CCOC(C)=O MVEAAGBEUOMFRX-UHFFFAOYSA-N 0.000 claims description 7
- 238000007327 hydrogenolysis reaction Methods 0.000 claims description 2
- 238000010561 standard procedure Methods 0.000 claims description 2
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 claims 4
- ZOGICTVLQDWPER-UFYCRDLUSA-N Phe-Tyr-Val Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](C(C)C)C(O)=O ZOGICTVLQDWPER-UFYCRDLUSA-N 0.000 claims 1
- 229940124599 anti-inflammatory drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000002785 anti-thrombosis Effects 0.000 abstract description 9
- 239000003146 anticoagulant agent Substances 0.000 abstract description 8
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 7
- 230000000259 anti-tumor effect Effects 0.000 abstract description 7
- 229940121363 anti-inflammatory agent Drugs 0.000 abstract description 2
- 239000003153 chemical reaction reagent Substances 0.000 abstract description 2
- 229960000103 thrombolytic agent Drugs 0.000 abstract description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 18
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 16
- 150000001875 compounds Chemical class 0.000 description 13
- 239000000243 solution Substances 0.000 description 13
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 10
- 210000001367 artery Anatomy 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 9
- 239000002504 physiological saline solution Substances 0.000 description 9
- 239000000843 powder Substances 0.000 description 8
- 210000003462 vein Anatomy 0.000 description 8
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 7
- 239000004698 Polyethylene Substances 0.000 description 7
- -1 polyethylene Polymers 0.000 description 7
- 229920000573 polyethylene Polymers 0.000 description 7
- 239000011780 sodium chloride Substances 0.000 description 7
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 229920000669 heparin Polymers 0.000 description 5
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 5
- ADFXKUOMJKEIND-UHFFFAOYSA-N 1,3-dicyclohexylurea Chemical compound C1CCCCC1NC(=O)NC1CCCCC1 ADFXKUOMJKEIND-UHFFFAOYSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 239000012047 saturated solution Substances 0.000 description 4
- 230000008961 swelling Effects 0.000 description 4
- 238000002627 tracheal intubation Methods 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 108010038807 Oligopeptides Proteins 0.000 description 3
- 102000015636 Oligopeptides Human genes 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000006837 decompression Effects 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 3
- 229960001008 heparin sodium Drugs 0.000 description 3
- 208000020442 loss of weight Diseases 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 230000002537 thrombolytic effect Effects 0.000 description 3
- 206010014025 Ear swelling Diseases 0.000 description 2
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 239000007832 Na2SO4 Substances 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 2
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 2
- 238000001467 acupuncture Methods 0.000 description 2
- 229940009456 adriamycin Drugs 0.000 description 2
- 230000023555 blood coagulation Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 210000005069 ears Anatomy 0.000 description 2
- 229920001971 elastomer Polymers 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 229960005356 urokinase Drugs 0.000 description 2
- CNBUSIJNWNXLQQ-NSHDSACASA-N (2s)-3-(4-hydroxyphenyl)-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid Chemical compound CC(C)(C)OC(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 CNBUSIJNWNXLQQ-NSHDSACASA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- 240000006409 Acacia auriculiformis Species 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- MDXGYYOJGPFFJL-QMMMGPOBSA-N N(alpha)-t-butoxycarbonyl-L-leucine Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)OC(C)(C)C MDXGYYOJGPFFJL-QMMMGPOBSA-N 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 244000061458 Solanum melongena Species 0.000 description 1
- 235000002597 Solanum melongena Nutrition 0.000 description 1
- OYOQKMOWUDVWCR-RYUDHWBXSA-N Tyr-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OYOQKMOWUDVWCR-RYUDHWBXSA-N 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 150000003851 azoles Chemical class 0.000 description 1
- YIRBOOICRQFSOK-NSHDSACASA-N benzyl (2s)-2-amino-3-methylbutanoate Chemical compound CC(C)[C@H](N)C(=O)OCC1=CC=CC=C1 YIRBOOICRQFSOK-NSHDSACASA-N 0.000 description 1
- 210000001168 carotid artery common Anatomy 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 238000002788 crimping Methods 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 210000003194 forelimb Anatomy 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229910000343 potassium bisulfate Inorganic materials 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 238000002444 silanisation Methods 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M sodium bicarbonate Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- 230000005740 tumor formation Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
本发明公开了Glu‑Leu‑Phe‑Tyr‑Val五肽,公开了它的制备方法,公开了它的抗炎活性,公开了它的抗肿瘤活性,公开了它的抗血栓活性及公开了它的溶血栓活性,因而本发明公开了它在制备抗炎药,抗肿瘤药物,抗血栓药物,溶血栓药物中的应用。
Description
技术领域
本发明涉及Glu-Leu-Phe-Tyr-Val五肽,涉及它的制备方法,涉及它的抗炎活性,涉及它的抗肿瘤活性,涉及它的抗血栓活性及涉及它的溶血栓活性,因而本发明涉及它在制备抗炎药, 抗肿瘤药物,抗血栓药物,溶血栓药物中的应用。本发明属于生物医药领域。
背景技术
发明抗肿瘤,抗血栓,溶血栓和抗凝血作用寡肽是发明人长期关注的领域。虽然发明人发明公开过一系列具有这些活性的寡肽,但是集这些活性为一体的寡肽一直没有得到。发明人发现，Glu-Leu-Phe-Tyr-Val五肽是集抗炎作用,抗肿瘤作用,抗血栓作用和溶血栓作用为一体的肽。根据这些发现发明人提出本发明。.
发明内容
本发明的第一个内容是提供序列为Glu-Leu-Phe-Tyr-Val的五肽。
本发明的第二个内容是提供Glu-Leu-Phe-Tyr-Val五肽的合成方法，该方法包括：
(1)在DCC和HOBt的催化下按照标准方法制备Boc-Tyr-Val-OBzl；
(2)Boc-Tyr-Val-OBzl在浓度为4N的氯化氢-乙酸乙酯溶液中,0℃脱Boc，转化成Tyr-Val-OBzl；
(3)在DCC和HOBt的催化下制备Boc-Leu-Phe-OBzl；
(4)Boc-Leu-Phe-OBzl在H2,Pd/C催化下，转化成Boc-Leu-Phe；
(5)在DCC和HOBt的催化下制备Boc-Leu-Phe-Tyr-Val-OBzl；
(6)Boc-Leu-Phe-Tyr-Val-OBzl在浓度为4N的氯化氢-乙酸乙酯溶液中,0℃脱Boc，转化成 Leu-Phe-Tyr-Val-OBzl；
(7)在DCC和HOBt的催化下制备Boc-Glu(OBzl)-Leu-Phe-Tyr-Val-OBzl；
(8)Boc-Glu(OBzl)-Leu-Phe-Tyr-Val-OBzl在Pd/C催化下氢解Boc-Glu-Leu-Phe-Tyr-Val；
(9)Boc-Glu-Leu-Phe-Tyr-Val在浓度为4N氯化氢-乙酸乙酯溶液中,0℃脱Boc转化成 Glu-Leu-Phe-Tyr-Val。
本发明的第三个内容是评价Glu-Leu-Phe-Tyr-Val五肽的抗炎作用。
本发明的第四个内容是评价Glu-Leu-Phe-Tyr-Val五肽的抗肿瘤作用。
本发明的第五个内容是评价Glu-Leu-Phe-Tyr-Val五肽的抗血栓作用。
本发明的第六个内容是评价Glu-Leu-Phe-Tyr-Val五肽的溶血栓作用。
附图说明
图1Glu-Leu-Phe-Tyr-Val的合成路线.i)二环己基碳二亚胺(DCC),1-羟基苯并三唑(HOBt),N- 甲基吗啉(NMM),四氢呋喃(THF)；ii)H2,Pd/C iii)4N HCl/EA,0℃。
具体实施方式
为了进一步阐述本发明，下面给出一系列实施例。这些实施例完全是例证性的，它们仅用来对本发明进行具体描述，不应当理解为对本发明的限制。
实施例1制备Boc-Tyr-Val-OBzl
冰浴下，2.81g(10mmol)Boc-Tyr溶解于少量无水四氢呋喃(THF)中，加入1.36g(10mmol)HOBt，加入2.47g(12mmol)DCC与少量无水THF的溶液，活化30分钟，加入2.07g(10mmol)Val-OBzl，用NMM调节pH＝9，反应结束后过滤除去二环己基脲(DCU)。滤液减压浓缩，残留物用乙酸乙酯溶解，再次过滤DCU，滤液用NaHCO3饱和溶液洗3遍，用NaCl饱和溶液洗3遍，5％的KHSO4溶液洗3遍，NaCl饱和溶液洗3遍，5％的NaHCO3溶液萃洗3遍，NaCl 饱和溶液萃洗3遍，乙酸乙酯层用无水Na2SO4干燥12小时，滤除Na2SO4，滤液减压浓缩，得到4.02g(85.5％)标题化合物，为无色粉末。ESI+-MS(m/e):472[M+H]+。
实施例2制备Tyr-Val-OBzl
冰浴下将4.7g(10mmol)Boc-Tyr-Val-OBzl用尽少量干燥过的乙酸乙酯溶解，搅拌10min，加入50mL氯化氢-乙酸乙酯溶液(4N)反应4h，原料点消失。反应混合物减压浓缩至干，残留物加40mL干燥过的乙酸乙酯溶解，得到的溶液减压浓缩至干。残留物按该操作重复3次。残留物加无水乙醚，用塑料铲研磨，减压浓缩除去乙醚。残留物按该操作重复3次。得到3.97g(99％)标题化合物，为无色粉末。ESI+-MS(m/e):372[M+H]+。
实施例3制备Boc-Leu-Phe-OBzl
按照实施例1的方法，2.31g(10mmol)Boc-Leu和2.55g(10mmol)Phe-OBzl得到3.98g (81.6％)标题化合物，为无色油状物。ESI+-MS(m/e):470[M+H]+。
实施例4制备Boc-Leu-Phe
将4.88g(10mmol)Boc-Leu-Phe-OBzl用甲醇溶解，加入488mg的10％的Pd/C。连接三通，减压抽除茄瓶中的空气后，反应瓶中充满H2，按该操作重复3次。反应20h后原料点消失。滤除Pd/C，旋干甲醇。得到3.67g(97％)标题化合物，为无色粉末。ESI+-MS(m/e):380[M+H]+。
实施例5制备Boc-Leu-Phe-Tyr-Val-OBzl
按照实施例1的方法，3.78g(10mmol)Boc-Leu-Phe和3.7g(10mmol)Tyr-Val-OBzl得到 4.23g(57.9％)标题化合物，为无色粉末。ESI+-MS(m/e):732[M+H]+。
实施例6制备Leu-Phe-Tyr-Val-OBzl
按照实施例2的方法，从7.3g(10mmol)Boc-Leu-Phe-Tyr-Val-OBzl得到6.1g(98％)标题化合物，为无色粉末。ESI+-MS(m/e):632[M+H]+。
实施例7制备Boc-Glu(OBzl)-Leu-Phe-Tyr-Val-OBzl
按照实施例1的方法，3.37g(10mmol)Boc-Glu(OBzl)和6.3g(10 mmol)Leu-Phe-Tyr-Val-OBzl得到3.35g(35.3％)标题化合物，为无色粉末。ESI+-MS(m/e):951 [M+H]+；1H-NMR(300MHz,DMSO-d6):δ/ppm＝9.14(s,1H),8.23(d,1H),7.95(m,2H),7.71(d, 1H),7.34(m,10H),7.16(m,5H),7.12(m,3H),6.63(d,2H),5.13(s,2H),5.08(s,2H),4.60(m, 1H),4.40(m,1H),4.25(m,2H),3.92(m,1H),2.90(m,2H),2.51(m,2H),2.33(m,2H),2.10(m,1H),1.80(m,2H),1.54(m,1H),1.30(s,11H),0.81(s,12H)。
实施例8制备Boc-Glu-Leu-Phe-Tyr-Val
按照实施例4的方法，从950mg(1mmol)的Boc-Glu-Leu-Phe-Tyr-Val-OBzl得到750mg(95.2％)标题化合物，为无色粉末。ESI+-MS(m/e):771[M+H]+。
实施例9制备Glu-Leu-Phe-Tyr-Val(GQ-E)
按照实施例2的方法，从769mg(1mmol)Boc-Glu-Leu-Phe-Tyr-Val-OBzl得到650mg(95.1％)标题化合物，为无色粉末。ESI+-MS(m/e):671[M+H]+；Mp 166.2～167.8℃. (c＝0.07，甲醇).IR:3273,3063,2961,2930,1710,1640,1515,1469,1443,1390,1369, 1218,1030,916,828,802,746,698,610,598,554.1H-NMR(300MHz,DMSO-d6):δ/ppm＝ 12.35(s,2H),9.19(s,1H),8.45(s,J＝8.1Hz 1H),8.23(d,J＝8.1Hz,3H),8.04(m,2H),7.15(s,5H), 7.05(d,J＝8.4Hz,2H),6.63(d,J＝8.4Hz,2H),4.54(m,2H),4.33(m,1H),4.17(m,1H),3.77(m,1H), 2.90(m,2H),2.70(m,2H),2.26(m,2H),2.06(m,1H),1.81(m,2H),1.39(m,3H),0.83(m,12H)。
实施例10评价Glu-Leu-Phe-Tyr-Val的抗炎活性
体重20±雄性小鼠口服1μmol/kg Glu-Leu-Phe-Tyr-Val(GQ-E)或1200μmol/kg阿司匹林或 0.2mL/20g生理盐水30分钟后，往小白鼠的左耳外廓涂二甲苯(0.04mL)，2小时后将小白鼠颈椎脱臼处死。将小鼠的左，右耳剪下，用直径7mm的打孔器在两耳的相同位置，取圆形耳片，分别称重，求出两圆耳片的重量差作为肿胀度。(肿胀度＝左耳原片重量-右耳原片重量)以肿胀度表示化合物的活性。本实验数据统计均采用t检验和方差分析，肿胀度以(x± SD mg)表示。结果表明，Glu-Leu-Phe-Tyr-Va治疗小鼠的耳肿胀度与生理盐水治疗小鼠的耳肿胀度相比具有显著性差异。表明化合物具有确切的抗炎活性。
表1 Glu-Leu-Phe-Tyr-Val(GQ-E)的抗炎活性
a)与生理盐水比p<0.05；n＝14.
实施例11评价Glu-Leu-Phe-Tyr-Val的抗肿瘤活性
无菌条件下取接种于ICR小鼠7-10天的S180肉瘤，加入适量生理盐水配制成瘤细胞悬液，细胞数为2×107/mL，接种于健康雄性ICR小鼠前肢腋皮下，每只小鼠注射0.2mL。肿瘤接种 24h后，小鼠每日腹腔注射0.2mL Glu-Leu-Phe-Tyr-Val(GQ-E)的生理盐水溶液，连续给药10 天，剂量为1μmol/kg/天；或小鼠每日腹腔注射0.2mL阿霉素的生理盐水溶液，连续给药10天，剂量为2μmol/kg/天；或小鼠每日腹腔注射0.2mL生理盐水，连续给药10天。实验进行至第11 天，称小鼠体重，乙醚麻醉剖取各组小鼠的肿瘤，称重并以瘤重表示化合物的活性，数据列入表2。结果表明1μmol/kg/天Glu-Leu-Phe-Tyr-Val治疗小鼠的瘤重明显小于生理盐水治疗小鼠的瘤重，而与剂量为2μmol/kg/天的阿霉素治疗小鼠的瘤重无显著性差异。Glu-Leu-Phe-Tyr-Val 显示确切的抗肿瘤活性。
表2 Glu-Leu-Phe-Tyr-Val(GQ-E)对S180荷瘤小鼠瘤重的影响
a)与生理盐水比p<0.01,与阿霉素比p>0.05；n＝15.
实施例12评价Glu-Leu-Phe-Tyr-Val的抗血栓活性
1)将聚乙烯管拉成一端为斜口的细管，定长为10.0cm，分别为右经静脉(管径较粗)及左颈动脉(管径较细)插管；中段聚乙烯管定长为8.0cm，血栓线压在颈动脉插管方向，插管前需在管中充满肝素。
2)体重250±雄性大鼠口服1μmol/kgGlu-Leu-Phe-Tyr-Val(GQ-E)或167μmol/kg阿司匹林或0.3 mL/100g生理盐水30分钟后，腹腔注射20％的乌拉坦进行麻醉。仰卧位将大鼠固定于鼠板上，剪开颈部皮肤，分离右颈总动脉及左颈静脉，血管下压线，结扎远心端，静脉靠远心端处剪一小口，进行静脉端插管，注射肝素，系线固定，再用动脉夹夹住动脉近心端，靠近远心端方向剪一小口，进行动脉端结扎，系线固定后松开动脉夹，建立体外循环旁路。循环15分钟后先剪断静脉端观察血液循环是否正常，若正常从动脉端取出血栓线，在纸上沾干浮血后称重，以栓重表示化合物的活性，数据列入表3。结果表明，Glu-Leu-Phe-Tyr-Val(GQ-E)治疗大鼠的血栓重明显小于生理盐水治疗大鼠的血栓重，显示确切的抗血栓活性。
表4 Glu-Leu-Phe-Tyr-Val(GQ-E)对大鼠栓重的影响
a)与生理盐水比p<0.01；n＝12.
实施例13评价Glu-Leu-Phe-Tyr-Val的溶栓活性
将大鼠静息饲养一天，随机分组，每组10只，禁食不禁水。
1)将体重250±雄性SD大鼠用20％乌拉坦溶液进行麻醉(6mL/kg腹腔)。麻醉后的大鼠固定于鼠板上，分离右侧颈总动脉，于近心端夹动脉夹，近心端和远心端分别传入手术线，在远心端插取血管，松开动脉夹取约1mL动脉血。迅速将动脉血注射入垂直的造栓管(长16mm，内径2.5mm，外径5mm，管底用1mL EP管底座)中，(注意不可有气泡)每个造栓管中注入0.1mL大鼠动脉血液，往管内迅速插入血栓固定螺栓(长20mm，)，血液凝固 40min，用针灸针取出血栓，称取血栓重量。
2)旁路插管由三部分组成，其中中段为聚乙烯胶管，长60mm，内径3.5mm，两端为相同的聚乙烯管，长100mm，内径1mm，外景2mm，该管的一段拉成尖管，另一端的外部套一段长7mm，外径3.5mm的聚乙烯管。三段管的内壁均为硅烷化。
3)将血栓包裹的血栓固定螺栓置于中段的聚乙烯胶管内，胶管的两端分别与两根聚乙烯的加粗端相套，用注射器通过尖管端注满肝素生理盐水溶液。将充满肝素钠的生理盐水溶液一端插入左侧静脉，另一端用注射器加入准确量的肝素钠抗凝后，拔掉肝素钠的注射器，插入动脉端。用头皮针将生理盐水(3mL/kg)或者尿激酶的生理盐水溶液(20000IU/kg)或 Glu-Leu-Phe-Tyr-Val(GQ-E)的生理盐水溶液(1μmol/kg)通过旁路管的中段，刺入远离血栓固定螺栓的近静脉处，打开动脉夹，使血流通过旁路管道从动脉流入静脉的时刻为循环起始时间，缓慢的将注射器中的液体注入到血液中(约6min),使生理盐水,尿激酶,Arg-Leu-Val-Cys-Val通过血液循环，按静脉-心脏-动脉的顺序作用到血栓上。60min后取出附有血栓的螺栓，蘸去浮血，记录重量。以血栓减重代表溶栓活性。数据列入表4。结果表明,Glu-Leu-Phe-Tyr-Val(GQ-E)治疗大鼠的血栓减重明显大于生理盐水治疗大鼠的血栓减重，显示确切的溶血栓活性。
表4 Glu-Leu-Phe-Tyr-Val(GQ-E)的溶栓活性
a)与生理盐水比p<0.01；n＝10。
Claims (6)
1.序列为Glu-Leu-Phe-Tyr-Val的五肽。
2.权利要求1的Glu-Leu-Phe-Tyr-Val五肽的制备方法，该方法包括：
(1)在DCC和HOBt的催化下按照标准方法制备Boc-Tyr-Val-OBzl；
(2)Boc-Tyr-Val-OBzl在浓度为4N的氯化氢-乙酸乙酯溶液中,0℃脱Boc，转化成Tyr-Val-OBzl；
(3)在DCC和HOBt的催化下制备Boc-Leu-Phe-OBzl；
(4)Boc-Leu-Phe-OBzl在Pd/C催化下，转化成Boc-Leu-Phe；
(5)在DCC和HOBt的催化下制备Boc-Leu-Phe-Tyr-Val-OBzl；
(6)Boc-Leu-Phe-Tyr-Val-OBzl在浓度为4N的氯化氢-乙酸乙酯溶液中,0℃脱Boc，转化成Leu-Phe-Tyr-Val-OBzl；
(7)在DCC和HOBt的催化下制备Boc-γ-羧基-OBzl-Glu-Leu-Phe-Tyr-Val-OBzl；
(8)Boc-γ-羧基-OBzl-Glu-Leu-Phe-Tyr-Val-OBzl在Pd/C催化下氢解Boc-Glu-Leu-Phe-Tyr-Val；
(9)Boc-Glu-Leu-Phe-Tyr-Val在浓度为4N氯化氢-乙酸乙酯溶液中,0℃脱Boc转化成Glu-Leu-Phe-Tyr-Val。
3.权利要求1的Glu-Leu-Phe-Tyr-Val五肽在制备抗肿瘤药物中的应用。
4.权利要求1的Glu-Leu-Phe-Tyr-Val五肽在制备抗栓药物的应用。
5.权利要求1的Glu-Leu-Phe-Tyr-Val五肽在制备溶栓药物的应用。
6.权利要求1的Glu-Leu-Phe-Tyr-Val五肽在制备抗炎药物的应用。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910381694.0A CN110105429B (zh) | 2015-06-23 | 2015-06-23 | Glu-Leu-Phe-Tyr-Val五肽,其合成,活性和应用 |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910381694.0A CN110105429B (zh) | 2015-06-23 | 2015-06-23 | Glu-Leu-Phe-Tyr-Val五肽,其合成,活性和应用 |
| CN201510352816.5A CN106317193B (zh) | 2015-06-23 | 2015-06-23 | 含Tyr-Val片段的肽,其合成、活性和应用 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510352816.5A Division CN106317193B (zh) | 2015-06-23 | 2015-06-23 | 含Tyr-Val片段的肽,其合成、活性和应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN110105429A true CN110105429A (zh) | 2019-08-09 |
| CN110105429B CN110105429B (zh) | 2021-06-08 |
Family
ID=57729406
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510352816.5A Expired - Fee Related CN106317193B (zh) | 2015-06-23 | 2015-06-23 | 含Tyr-Val片段的肽,其合成、活性和应用 |
| CN201910380965.0A Expired - Fee Related CN110105428B (zh) | 2015-06-23 | 2015-06-23 | Leu-Arg-Ala-Pro-Leu-Tyr-Val七肽,其合成,活性和应用 |
| CN202110015076.1A Expired - Fee Related CN112812152B (zh) | 2015-06-23 | 2015-06-23 | Glu-Leu-Phe-Tyr-Val五肽的合成及抗炎应用 |
| CN202110015078.0A Expired - Fee Related CN112794879B (zh) | 2015-06-23 | 2015-06-23 | Glu-Leu-Phe-Tyr-Val五肽的合成及应用 |
| CN201910381694.0A Expired - Fee Related CN110105429B (zh) | 2015-06-23 | 2015-06-23 | Glu-Leu-Phe-Tyr-Val五肽,其合成,活性和应用 |
Family Applications Before (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510352816.5A Expired - Fee Related CN106317193B (zh) | 2015-06-23 | 2015-06-23 | 含Tyr-Val片段的肽,其合成、活性和应用 |
| CN201910380965.0A Expired - Fee Related CN110105428B (zh) | 2015-06-23 | 2015-06-23 | Leu-Arg-Ala-Pro-Leu-Tyr-Val七肽,其合成,活性和应用 |
| CN202110015076.1A Expired - Fee Related CN112812152B (zh) | 2015-06-23 | 2015-06-23 | Glu-Leu-Phe-Tyr-Val五肽的合成及抗炎应用 |
| CN202110015078.0A Expired - Fee Related CN112794879B (zh) | 2015-06-23 | 2015-06-23 | Glu-Leu-Phe-Tyr-Val五肽的合成及应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (5) | CN106317193B (zh) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109776652B (zh) * | 2019-01-30 | 2020-08-18 | 浙江省医学科学院 | 鳕鱼皮寡肽及其分离纯化方法和在制备ɑ-葡萄糖苷酶抑制剂及抗Ⅱ型糖尿病药物中的应用 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8723485D0 (en) * | 1987-10-07 | 1987-11-11 | Erba Farmitalia | Solution synthesis of octapeptide |
| ES2107525T3 (es) * | 1990-12-17 | 1997-12-01 | Yakult Honsha Kk | Peptido trombolitico, su produccion y agente trombolitico. |
| ATE179990T1 (de) * | 1993-01-13 | 1999-05-15 | Takeda Chemical Industries Ltd | Cyclische pentapeptide mit beta-turn und gamma- turn |
| JPH083191A (ja) * | 1994-06-15 | 1996-01-09 | Kuraray Co Ltd | 抗血栓性ペプチドおよびこれを固定化した医療用具 |
| EP1803731A4 (en) * | 2004-09-28 | 2011-01-26 | Univ Gunma Nat Univ Corp | METHOD FOR THE PRODUCTION OF A PARTEPEPTIDE OF THE ENOLASEPROTEIN FROM PLASMODIUM FALCIPARUM |
| CN1312176C (zh) * | 2005-04-15 | 2007-04-25 | 赵恩成 | 一种蝎毒多肽及其制备方法 |
| CN101437517A (zh) * | 2006-04-14 | 2009-05-20 | 夏尔有限责任公司 | 提高共价结合的化合物的镇痛效果、减少其副作用和防止其滥用的组合物和方法 |
| CN102477075B (zh) * | 2010-11-30 | 2013-08-14 | 首都医科大学 | 用于抗血栓的寡肽及其制备方法和应用 |
| CN102485748B (zh) * | 2010-12-01 | 2013-09-25 | 首都医科大学 | 具有靶向性溶血栓活性的寡肽、其制备方法和应用 |
| CN102485747B (zh) * | 2010-12-01 | 2013-09-25 | 首都医科大学 | 具有靶向性溶血栓活性的寡肽、其制备方法和应用 |
| CN104610424B (zh) * | 2011-12-13 | 2018-08-17 | 首都医科大学 | Lys(Pro-Ala-Lys)姜黄素衍生物、其合成及在医学中的应用 |
| CN103450338B (zh) * | 2012-05-29 | 2016-08-24 | 首都医科大学 | 杂环羧酸修饰的胸腺五肽，其制备，抗肿瘤作用和应用 |
| CN103450342B (zh) * | 2012-06-01 | 2015-08-05 | 首都医科大学 | 四氢异喹啉-3-羧酸修饰的pargd七肽、其合成、抗血栓活性和应用 |
| CN103539837A (zh) * | 2012-07-15 | 2014-01-29 | 彭莉 | 1-甲基-β-咔啉-3-甲酰RGD肽、其合成、纳米结构、抗血栓作用和应用 |
| TWI568747B (zh) * | 2012-09-05 | 2017-02-01 | 上海晟順生物科技有限公司 | 同時具溶血栓、清除自由基和血栓靶向功能的新穎化合物及其製備方法和用途 |
-
2015
- 2015-06-23 CN CN201510352816.5A patent/CN106317193B/zh not_active Expired - Fee Related
- 2015-06-23 CN CN201910380965.0A patent/CN110105428B/zh not_active Expired - Fee Related
- 2015-06-23 CN CN202110015076.1A patent/CN112812152B/zh not_active Expired - Fee Related
- 2015-06-23 CN CN202110015078.0A patent/CN112794879B/zh not_active Expired - Fee Related
- 2015-06-23 CN CN201910381694.0A patent/CN110105429B/zh not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN110105429B (zh) | 2021-06-08 |
| CN106317193B (zh) | 2019-07-26 |
| CN112794879B (zh) | 2022-09-02 |
| CN112812152B (zh) | 2022-09-02 |
| CN112812152A (zh) | 2021-05-18 |
| CN112794879A (zh) | 2021-05-14 |
| CN110105428B (zh) | 2022-08-05 |
| CN110105428A (zh) | 2019-08-09 |
| CN106317193A (zh) | 2017-01-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107686483A (zh) | 七环缩醛,其制备,抗栓活性和应用 | |
| CN106317185B (zh) | His-Gly-Tyr-Asp，其合成，活性和应用 | |
| CN110105429A (zh) | Glu-Leu-Phe-Tyr-Val五肽,其合成,活性和应用 | |
| CN106317191B (zh) | Thr-Val-Gly-Cys-Ser,其合成,活性和应用 | |
| CN108929372B (zh) | 1R-甲基-β-四氢咔啉酰-K(GRPAK)-RGDV,其合成,活性和应用 | |
| CN106279362B (zh) | Arg-Leu-Val-Cys-Val，其合成，药理活性和应用 | |
| CN108948146A (zh) | 1R-甲基-β-四氢咔啉酰-K(ARPAK)-RGDV, 其合成, 活性和应用 | |
| CN106432417A (zh) | 五甲氧色胺基羰丙酰-rpak,其制备,活性和应用 | |
| CN106317171A (zh) | 环组氨酰-kk,其合成,血栓相关活性及应用 | |
| CN106608905A (zh) | 四氢异喹啉-3-甲酰-k(grpak)rgdv,其合成,活性及应用 | |
| CN106317177A (zh) | Gly-Phe-Pro,其合成,活性和应用 | |
| CN108948145A (zh) | 1R-甲基-β-四氢咔啉酰-K(PAK)-RGDV,其合成,活性和应用 | |
| CN108948155A (zh) | 1R-甲基-β-四氢咔啉酰-K(QRPAK)-RGDV, 其合成, 活性和应用 | |
| CN106432413A (zh) | 五甲氧色胺基羰丙酰-k(pak),其制备,活性和应用 | |
| CN106317192B (zh) | 3，4-二羟基-f(pak)-rgd-aa，其合成，活性及应用 | |
| CN106317198B (zh) | GRPAK-The-RGDV，其制备，活性及应用 | |
| CN107459557A (zh) | 左旋维c-2-氧乙酰-grpak,其合成,活性和应用 | |
| CN106317172A (zh) | Pro-Ser,其合成,活性和应用 | |
| CN106336450B (zh) | RGDV-The-GRPAK十肽，其制备，活性及应用 | |
| CN106349333B (zh) | The-K(KAPRG)RGDV十一肽，其制备，活性及应用 | |
| CN106589058A (zh) | 多巴-肽的合成,血栓相关活性及应用 | |
| CN106317199B (zh) | The-GRPAKRGDV十肽,其制备,活性及应用 | |
| CN106317187B (zh) | 五甲氧色胺基羰丙酰-pak肽,其制备,活性和应用 | |
| CN106589059A (zh) | N-(a)-2,3-二羟基异喹啉-7-甲酰-rgdv/f,其合成,活性及应用 | |
| CN106317189B (zh) | 五甲氧色胺基羰丙酰-rpak肽,其制备,活性和应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20210608 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |